Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7869938 | 0.97 | PTGS1 (0.50) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28038731 | 0.97 | PTGS1 (0.50) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL9842274 | 0.89 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL375597 | 0.89 | TSHR (0.53) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL263732 | 0.89 | APP (0.46) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL8772862 | 0.87 | LMNA (0.55) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL7527691 | 0.87 | MEN1 (0.55) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL3488844 | 0.87 | PTGS1 (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL7039096 | 0.87 | TSHR (0.50) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL14599270 | 0.87 | PTGS1 (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210212321-A1 | STABILIZED FUNGICIDAL COMPOSITION COMPRISING CYCLODEXTRIN | BAYER CROPSCIENCE LP | 2021-07-15 | — | — | US | claimed |
| EP-2152078-B1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS INC (US) | 2021-01-13 | — | — | EP | claimed |
| CN-104800210-B | Preparation comprising clopidogrel and sulfoalkyl ether cyclodextrin and its application method | 锡德克斯药物公司 | 2019-08-06 | — | — | CN | claimed |
| US-9925274-B2 | Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient | SAPIOTEC GMBH (DE) | 2018-03-27 | — | — | US | claimed |
| EP-2919791-B1 | DELPHINIDINCOMPLEX AS ANTIPHLOGISTIC OR IMMUNOSUPPRESSIVE AGENT | SAPIOTEC GMBH (DE) | 2017-03-22 | — | — | EP | claimed |
| US-20150306247-A1 | DELPHINIDIN COMPLEX AS AN ANTIPHLOGISTIC OR IMMUNOSUPPRESSIVE ACTIVE INGREDIENT | SAPIOTEC GMBH (DE) | 2015-10-29 | — | — | US | claimed |
| CN-104800210-A | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS INC | 2015-07-29 | — | — | CN | claimed |
| US-9085525-B2 | Processes employing cyclodextrin derivative quaternary salts | MATOS JOSE R (US) | 2015-07-21 | — | — | US | claimed |
| CN-101686681-B | Formulations comprising clopidogrel and sulfoalkyl ether cyclodextrins and methods of use thereof | CYDEX PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | claimed |
| US-20140046061-A1 | Processes Employing Cyclodextrin Derivative Quaternary Salts | MATOS JOSE R (US) | 2014-02-13 | — | — | US | claimed |
| EP-1742535-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005117911-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| WO-2005104712-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | claimed |
| CN-1079824-C | Ester oligomers suitable for use as soil release agents in detergent compositions | PROCTER & GAMBLE (US) | 2002-02-27 | — | — | CN | claimed |
| EP-0797655-B1 | ESTER OLIGOMERS SUITABLE AS SOIL RELEASE AGENTS IN DETERGENT COMPOSITIONS | PROCTER & GAMBLE (US) | 1999-04-14 | — | — | EP | claimed |
| CN-1175277-A | Ester oligomers suitable for use as soil release agents in detergent compositions | PROCTER & GAMBLE (US) | 1998-03-04 | — | — | CN | claimed |
| US-5691298-A | DIHYDROXY OR POLYHYDROXY SULFONATES WITH ESTER GROUPS, TEREPHTHALOYL AND UNSULFONATE AND CAPPING GROUPS | THE PROCTER & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| EP-0797655-A2 | ESTER OLIGOMERS SUITABLE AS SOIL RELEASE AGENTS IN DETERGENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1997-10-01 | — | — | EP | claimed |
| WO-1996018715-A2 | ESTER OLIGOMERS SUITABLE AS SOIL RELEASE AGENTS IN DETERGENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1996-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210212321-A1 | STABILIZED FUNGICIDAL COMPOSITION COMPRISING CYCLODEXTRIN | CYP3A43, POR, CBR3 | PTGS1 4019/4885PDE4A 963/4885LMNA 4024/4885 |
| US-20150306247-A1 | DELPHINIDIN COMPLEX AS AN ANTIPHLOGISTIC OR IMMUNOSUPPRESSIVE ACTIVE INGREDIENT | HLA-DRB1, CD74, HLA-C | PTGS1 2490/4885PDE4A 3162/4885LMNA 4668/4885 |
| US-20140046061-A1 | Processes Employing Cyclodextrin Derivative Quaternary Salts | PICALM, SI, PDCD2L | PTGS1 4149/4885PDE4A 2309/4885LMNA 4539/4885 |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | SORD, STS, SULT1A1 | PTGS1 4572/4885PDE4A 991/4885LMNA 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.